CVS delays including Gilead’s new HIV prevention shot in drug coverage
CVS Health has opted to postpone adding Gilead Sciences’ latest HIV prevention medication to its pharmacy benefit coverage, a decision that could influence patient access to the breakthrough injectable. The drug, which was recently approved by regulators, is being hailed as a major advancement in HIV prevention strategies, offering a longer-acting alternative to existing daily oral medications.Gilead’s novel strategy focuses on both ease of use and effectiveness, aiming to enhance compliance for people vulnerable to HIV transmission. Instead of the usual pre-exposure prophylaxis (PrEP) pills that must be taken every day, this injection is given at extended intervals, lessening the…